Source AP ©

Johnson & Johnson 3rd-quarter profit decreases on 528 million dollars

Johnson&Johnson’s 3rd quarter profit fell about 8 percent because of charges for cutting jobs, primarily in its stent-making and pharmaceuticals businesses.

The company earned $2.55 billion (EUR1.8 billion), or 88 cents per share, compared with a profit of $2.76 billion, or 94 cents per share during the same period a year prior.

Revenue rose to $14.97 billion (EUR10.6 billion) from $13.29 billion, helped by strong results in international markets.

In July, J&J said it would reduce its global work force by up to 4 percent, or up to 4,820 jobs, to cut costs due to slumping sales of heart stents and its No. 2 drug, plus looming patent expirations. The third-quarter results include a related $528 million (EUR373.14 million) charge. Excluding that, J&J posted earnings of $1.06 per share.

Analysts polled by Thomson Financial expected profit of 99 cents per share on revenue of $14.84 billion (EUR10.5 billion).

The company increased its earnings guidance for the full-year to between $4.10 and $4.13 per share from between $4.02 to $4.07 per share. The guidance excludes restructuring charges and special items.

Comments
Attempts to blame Russia for MH17 disaster continue zealously
Skripals fall under heavy British pressure
Iran's next moves on nuclear deal much more important - Kremlin
Russian air defences ready to shoot down NATO drones and reconnaissance aircraft over Crimea
Kremlin wants foreign invaders out of Syria
Russian air defences ready to shoot down NATO drones and reconnaissance aircraft over Crimea
Elon Musk and a Truth called Pravda
Russian air defences ready to shoot down NATO drones and reconnaissance aircraft over Crimea
The Royal Wedding and the Silly Season
The Royal Wedding and the Silly Season
The Royal Wedding and the Silly Season
The Royal Wedding and the Silly Season
Attempts to blame Russia for MH17 disaster continue zealously
Ukraine's exit from Commonwealth of Independent States will affect common Ukrainians most
Kremlin on failed nuclear missile tests: 'Listen to President Putin and believe him!'
Russian air defences ready to shoot down NATO drones and reconnaissance aircraft over Crimea
Russian air defences ready to shoot down NATO drones and reconnaissance aircraft over Crimea
Russian stock market, national currency collapse because of US sanctions
Russian stock market, national currency collapse because of US sanctions
Russians massively break traffic rules on Crimea Bridge
Putin’s spokesman: Total blockade of Russia impossible